Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo

Oncogene

Volumn 31, Issue 22, 2012, Pages 2725-2737

  Ramachandran, I ^a   Thavathiru, E ^a   Ramalingam, S ^b,c   Natarajan, G ^b   Mills, W K ^a   Benbrook, D M ^b   Zuna, R ^b   Lightfoot, S ^b   Reis, A ^b   Anant, S ^b,c   Queimado, L ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

catenin; Apoptosis; Cervical cancer; Hypermethylation; Wnt; Wnt inhibitory factor 1 (WIF1)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APOPTOSIS INDUCING FACTOR; BETA CATENIN; CYCLIN D1; HERMES ANTIGEN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; WNT INHIBITORY FACTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; AZACITIDINE; BETA CATENIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CERVIX UTERI; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS; WNT PROTEINS;

MUS;

EID: 84861660394     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.455     Document Type: Article

References (60)

1. Abbasi AM, Chester KA, Talbot IC, Macpherson AS, Boxer G, Forbes A et al. (1993). CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer 29A: 1995-2002. (Pubitemid 23324361)
2. Agarwal ML, Agarwal A, Taylor WR, Stark GR. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497.
3. Ahn WS, Bae SM, Lee JM, Namkoong SE, Yoo JY, Seo YS et al. (2004). Anti-cancer effect of adenovirus p53 on human cervical cancer cell growth in vitro and in vivo. Int J Gynecol Cancer 14: 322-332. (Pubitemid 38533905)
4. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW et al. (2006). Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27: 1341-1348. (Pubitemid 43985409)
5. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS et al. (2001). Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 81: 341-347.
6. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. (2008). Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121: 737-746. (Pubitemid 351578109)
7. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S et al. (2006). Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Eur J Gynaecol Oncol 27: 215-223. (Pubitemid 43953413)
8. Byun T, Karimi M, Marsh JL, Milovanovic T, Lin F, Holcombe RF. (2005). Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol 58: 515-519. (Pubitemid 40646873)
9. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH et al. (2009). Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol 112: 301-306.
10. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS et al. (1997). Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151: 671-677. (Pubitemid 27385598)
11. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. (2004). Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447. (Pubitemid 39564581)
12. Gherghe CM, Duan J, Gong J, Rojas M, Klauber-Demore N, Majesky M et al. (2011). Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a HGF-dependent manner. FASEB J 25: 1836-1843.
13. Hemann MT, Lowe SW. (2006). The p53-Bcl-2 connection. Cell Death Differ 13: 1256-1259. (Pubitemid 44057454)
14. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B, Richter CE et al. (2006). Pattern of invasion is of prognostic value in surgically treated cervical cancer patients. Gynecol Oncol 103: 906-911. (Pubitemid 44821312)
15. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH et al. (1999). A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398: 431-436. (Pubitemid 29180376)
16. Huber AH, Weis WI. (2001). The structure of the b-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by b-catenin. Cell 105: 391-402. (Pubitemid 32455345)
17. Jamora C, DasGupta R, Kocieniewski P, Fuchs E. (2003). Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 422: 317-322. (Pubitemid 36378359)
18. Johnson CL, Lu D, Huang J, Basu A. (2002). Regulation of p53 stabilization by DNA damage and protein kinase C. Mol Cancer Ther 1: 861-867.
19. Jones M, Tussey L, Athanasou N, Jackson DG. (2000). Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 275: 7964-7974. (Pubitemid 30159706)
20. Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G, Reinthaller A et al. (1995). Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 31: 1706-1709.
21. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M et al. (2009). Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119: 837-851.
22. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S et al. (2009). Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 69: 8603-8610.
23. Kawano Y, Kypta R. (2003). Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634. (Pubitemid 36857216)
24. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B et al. (2007). Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 133: 733-737. (Pubitemid 46274732)
25. Koskimaa HM, Kurvinen K, Costa S, Syrjänen K, Syrjänen S. (2010). Molecular markers implicating early malignant events in cervical carcinogenesis. Cancer Epidemiol Biomarkers Prev 19: 2003-2012.
26. Laux H, Tomer R, Mader MT, Smida J, Budczies J, Kappler R et al. (2004). Tumor-associated E-cadherin mutations do not induce Wnt target gene expression, but affect E-cadherin repressors. Lab Invest 84: 1372-1386. (Pubitemid 40063701)
27. Lee EJ, Jo M, Rho SB, Park K, Yoo YN, Park J et al. (2009). Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 124: 287-297.
28. Li J, Yuan J. (2008). Caspases in apoptosis and beyond. Oncogene 27: 6194-6206.
29. Lin YC, You L, Xu Z, He B, Yang CT, Chen JK et al. (2007). Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 18: 379-386. (Pubitemid 46709349)
30. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R et al. (2001). The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61: 2256-2260. (Pubitemid 32692056)
31. Lu S, Zhang B, Wang Z. (2005). Expression of survivin, cyclin D1, p21(WAF1), caspase-3 in cervical cancer and its relation with prognosis. J Huazhong Univ Sci Technolog Med Sci 25: 78-81.
32. MacDonald BT, Tamai K, He X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
33. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler Met al. (2005). Serum vascular endothelial growth factor C (VEGFC) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol 98: 467-483. (Pubitemid 41169160)
34. Mikels AJ, Nusse R. (2006). Wnts as ligands: processing, secretion and reception. Oncogene 25: 7461-7468. (Pubitemid 44885745)
35. Nusse R. (2005). Wnt signaling in disease and in development. Cell Res 15: 28-32. (Pubitemid 41653961)
36. Orian-Rousseau V. (2010). CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277.
37. Parkin DM, Bray F. (2006). Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl 3): S3/11-S3/25.
38. Perez-Plasencia C, Duenas-Gonzalez A, Alatorre-Tavera B. (2008). Second hit in cervical carcinogenesis process: involvement of Wnt/beta catenin pathway. Int Arch Med 1: 10.
39. Phoophitphong T, Hanprasertpong J, Dechsukhum C, Geater A. (2007). Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J Obstet Gynaecol Res 33: 840-848. (Pubitemid 350086518)
40. Polyak K, Weinberg RA. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
41. Queimado L, Obeso D, Hatfield MD, Yang Y, Thompson DM, Reis AMC. (2008). Dysregulation of Wnt pathway components in human salivary gland tumors. Arch Otolaryngol Head Neck Surg 134: 94-101. (Pubitemid 351159282)
42. Robertson KD. (2001). DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139-3155. (Pubitemid 32553570)
43. Shinohara A, Yokoyama Y, Wan X, Takahashi Y, Mori Y, Takami T et al. (2001). Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol 82: 450-455. (Pubitemid 32826443)
44. Silva-Filho AL, Traiman P, Triginelli SA, Reis FM, Pedrosa MS, Miranda D et al. (2006). Association between CD31 expression and histopathologic features in stage IB squamous cell carcinoma of the cervix. Int J Gynecol Cancer 16: 757-762.
45. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. (2005). Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 96: 308-318. (Pubitemid 40279905)
46. Speiser P, Wanner C, Tempfer C, Mittelbock M, Hanzal E, Bancher-Todesca D et al. (1997). CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer 74: 185-188. (Pubitemid 27234508)
47. Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F et al. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 8: 458-468.
48. Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K et al. (2005). Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24: 7946-7952. (Pubitemid 41715201)
49. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N et al. (2001). Mutations of the beta-and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 85: 64-68. (Pubitemid 32695717)
50. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T et al. (2006). Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 12: 383-391. (Pubitemid 43166125)
51. Uren A, Fallen S, Yuan H, Usubutun A, Kucukali T, Schlegel R et al. (2005). Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res 65: 6199-6206. (Pubitemid 40994405)
52. Vijayalakshmi N, Selvaluxmi G, Mahji U, Rajkumar T. (2002). C-myc oncoprotein expression and prognosis in patients with carcinoma of the cervix: an immunohistochemical study. Eur J Gynaecol Oncol 23: 135-138. (Pubitemid 34297117)
53. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV et al. (2007). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27: 1905-1915.
54. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al. (1999). Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523. (Pubitemid 29094101)
55. Wissmann C, Wild P, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M et al. (2003). WIF1, a component of the Wnt pathway, is downregulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212.
56. Woodman CB, Collins SI, Young LS. (2007). The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11-22. (Pubitemid 46020844)
57. Wright M, Aikawa M, Szeto W, Papkoff J. (1999). Identification of a Wnt-responsive signal transduction pathway in primary endothelial cells. Biochem Biophys Res Commun 263: 384-388. (Pubitemid 29467205)
58. Yee D, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S et al. (2010). The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 9: 162.
59. Yu Q, Toole BP, Stamenkovic I. (1997). Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186: 1985-1996. (Pubitemid 28013682)
60. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. (2009). Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 219: 3-15.